Antibodies to the Druggable Genome
Abgent’s core focus on development of antibodies against regulatory enzymes, beginning with the design and manufacture of antibodies against over 1000 epitopes spanning the human kinome, has resulted in an extensive antibody portfolio against a broad cross-section of proteins comprising the druggable genome. We have expanded on this selection of pharma-centric antibody products and announce a comprehensive collection of over 200 qualified antibodies targeting druggable proteins. New protein targets in this collection include: EIF4B, EIF4E, HGF, VEGF1, VEGF2, VEGF3, STK11, MAPK1, MAPK3, and PI3KCB, PI3KR1, PI3KCG and PI3KR5.
See product listing.
Autophagy APG16L Antibodies – Marker for Crohn Disease
 Abgent’s autophagy antibodies are directed against human homologs of proteins indentified in the autophagy process, including APG16L, a member of the APG12-APG5-APG16L complex, which plays a role in the formation of the autophagosome. A genome-wide association scan of nonsynonymous SNPs has identified a susceptibility variant for Crohn disease in ATG16L. Drs. J. Hampe, S. Schreiber, P. Rosenstiel et al. used Abgent’s APG16L antibody (Catalog No. AP1817b) on a patient biopsy to confirm colonic Crohn disease.
EpiShot™ Premiere Polyclonal Antibody Service
Combine our proprietary prediction tool with best-in-class antibody development expertise. Let Abgent scientists design an optimal peptide immunogen derived from your target protein using our EpiShot™ Antigen Prediction Screen which analyzes critical parameters including: surface exposure and topology, solubility, optimal peptide length, post-translational modifications, sequence homology, structural information and species cross-reactivity.
|
NEW PRODUCTS (296) 
